Material Agreements

AIRGAIN INC entered into Sales Agreement with Craig-Hallum Capital Group LLC valued at up to $5.0 million (effective 2024-03-06).

“On March 6, 2024, Airgain, Inc. (the “Company”) entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Craig-Hallum Capital Group LLC (the “Agent”), under which the Company may, from time to time, sell shares of the Company’s common stock having an aggregate offering price of up to $5.0 million in “at the market” offerings through or to the Agent, as sales agent or principal.”

ALIMERA SCIENCES INC amended Seventh Amendment with SLR Capital Partners, LLC (effective 2024-03-06).

“On March 6, 2024, Alimera Sciences, Inc. (“Alimera”) entered into the Seventh Amendment (the “Amendment”) to its Loan and Security Agreement dated December 31, 2019, with SLR Capital Partners, LLC (“SLR”) as collateral agent, and the lenders party thereto”

CoreCivic, Inc. entered into Underwriting Agreement with Citizens JMP Securities, LLC, as representative of the underwriters valued at $500 million (effective 2024-03-05).

“On March 5, 2024, CoreCivic, Inc., a Maryland corporation (the “Company”), and the subsidiary guarantors of the Company named therein (the “Guarantors”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citizens JMP Securities, LLC, as representative of the underwriters listed on Schedule A thereto (the “Underwriters”), for the issuance and sale of $500 million aggregate principal amount of the Company’s 8.250% senior unsecured notes due 2029 (the “Notes”).”

RGC RESOURCES INC amended Note Modification Agreement with Atlantic Union Bank (effective 2024-03-06).

“Also, on March 6, 2024, Midstream entered into a Note Modification Agreement (the "Agreement") with the Bank related to the unsecured Promissory Note (the "Note") with an original principal amount of $8,000,000 dated November 1, 2021, as amended.”

RGC RESOURCES INC amended Sixth Amendment to Credit Agreement with Atlantic Union Bank (effective 2024-03-06).

“On March 6, 2024, RGC Midstream, LLC (“Midstream”), a wholly owned subsidiary of RGC Resources, Inc. (“Resources”), entered into the Sixth Amendment to Credit Agreement (the "Amendment") with Atlantic Union Bank (the "Bank").”

Viracta Therapeutics, Inc. amended Second Amendment (the “Second Amendment”) to the Loan and Security Agreement with Silicon Valley Bank, now a division of First-Citizens Bank and Trust Company, and Oxford Finance LLC valued at $5.0 million (effective 2024-03-01).

“On March 1, 2024, the Company entered into a Second Amendment (the “Second Amendment”) to the Loan and Security Agreement by and among the Company and Silicon Valley Bank, now a division of First-Citizens Bank and Trust Company, and Oxford Finance LLC, dated November 4, 2021, as previously amended, providing for a modification of the loan amortization period and a pro rata reduction in the prospective debt amortization schedule, in exchange for a partial prepayment of the term loan.”

Viracta Therapeutics, Inc. amended Amendment No. 1 (the “XOMA Amendment”) to the Royalty Purchase Agreement with XOMA (US) LLC valued at $5.0 million (effective 2024-03-04).

“On March 4, 2024, in connection with the entry into the Day One Amendment, the Company entered into an Amendment No. 1 (the “XOMA Amendment”) to the Royalty Purchase Agreement, dated as March 22, 2021, by and between the Company and XOMA (US) LLC, modifying the economic value-share under the Royalty Purchase Agreement, by which the Company has retained the right, under certain circumstances, to participate in a pre-commercialization, event-based milestone up to $5.0 million.”

Viracta Therapeutics, Inc. amended Amendment No. 1 (the “Day One Amendment”) to the License Agreement for RAF with Day One Biopharmaceuticals, Inc., successor in interest to DOT Therapeutcs-1, Inc. valued at $5.0 million (effective 2024-03-04).

“On March 4, 2024, the Company entered into an Amendment No. 1 (the “Day One Amendment”) to the License Agreement for RAF, dated as of December 16, 2019, by and between the Company and Day One Biopharmaceuticals, Inc., successor in interest to DOT Therapeutcs-1, Inc., to monetize a pre-commercialization, event-based milestone for $5.0 million to be received in March 2024, thereby reducing the milestone percentage under the agreement.”

WD 40 CO entered into Quota Purchase Agreement with M12 Participações Empresariais S.A. valued at approximately $6.9 million USD (effective 2024-03-04).

“On March 4, 2024 (“Closing Date”), WD-40 Holding Company Brasil Ltda. (“Buyer”), a wholly-owned subsidiary of WD-40 Company (“Company”), acquired all of the issued and outstanding capital stock of Brazilian distributor, Theron Marketing Ltda. (“Theron”), from M12 Participações Empresariais S.A. (“Seller”) in a cash-for-stock transaction. The approximate purchase price of $6.9 million USD is subject to a 90-day post closing adjustment.”

AMERICAN TOWER CORP /MA/ entered into Supplemental Indenture No. 5 with U.S. Bank Trust Company, National Association valued at $650.0 million aggregate principal amount of its 5.200% senior unsecured notes due 2029 and $650.0 m (effective 2024-03-07).

“The Company issued the Notes under an indenture dated as of June 1, 2022 (the "Base Indenture"), as supplemented by a supplemental indenture dated as of March 7, 2024 (the "Supplemental Indenture No. 5" and, together with the Base Indenture, the "Indenture"), each between the Company and U.S. Bank Trust Company, National Association, as trustee (the "Trustee").”

LAUREATE EDUCATION, INC. entered into Stock Purchase Agreement with ILM Investments Limited Partnership, Torreal Sociedad de Capital Riesgo S.A., Pedro del Corro García-Lomas, Ana Gómez Cuesta and José Diaz-Rato Revuelta valued at 2,606,507 shares at $12.62 per share, aggregate purchase price $32,894,118 (effective 2024-03-05).

“Effective March 5, 2024, Laureate Education, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with each of ILM Investments Limited Partnership, Torreal Sociedad de Capital Riesgo S.A., Pedro del Corro García-Lomas, Ana Gómez Cuesta and José Diaz-Rato Revuelta (each, a “Seller” and together, the “Sellers”), pursuant to which the Company agreed to purchase an aggregate of 2,606,507 shares of the Company’s common stock from the Sellers at a purchase price of $12.62 per share for an aggregate purchase price of $32,894,118 (the “Purchase Price”).”

Clarus Corp terminated Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto (effective 2024-02-29).

“Contemporaneous with the closing of the Sale Transaction (hereinafter defined), Clarus Corporation (the “Company”) directed $135,013,124 of the proceeds from the closing of the Sale Transaction to payoff any and all outstanding borrowings under that certain Amended and Restated Credit Agreement, dated April 18, 2022, by and among the Company, Black Diamond Retail, Inc., Black Diamond Retail – Alaska, LLC, Sierra Bullets, L.L.C. (“Sierra”), SKINourishment, LLC, Black Diamond Retail – Colorado, LLC, Black Diamond Retail – Montana, LLC, Black Diamond Retail – Wyoming, LLC, Barnes Bullets-Mona, LLC (“Barnes”), Black Diamond Retail – Oregon, LLC, Black Diamond Retail – Vermont, LLC (collectively with the Company, the “Borrowers”) and the other loan parties party thereto (together with the Borrowers, each a “Loan Party”, and collectively, the “Loan Parties”) and JPMorgan Chase Bank, N.A., as administrative agent (the “Administrative Agent”) and the lenders party thereto (the “Amended and Res”

Mitesco, Inc. entered into a notes offering with Cavalry Fund, AJB and Mercer Street Capital valued at $50,000 of proceeds each.

“the Company entered into a lending agreements with each of three (3) of its historical institutional investors, Cavalry Fund, AJB and Mercer Street Capital (“the Lenders”). The notes provide $50,000 of proceeds each”

IMMUCELL CORP /DE/ amended Amending Agreement with Norbrook Laboratories Limited (effective 2024-03-04).

“On March 4, 2024, ImmuCell Corporation (the “Company”) entered into an Amending Agreement (the “Amendment”) with Norbrook Laboratories Limited (“Norbrook”), which Amendment amends that certain Development Services and Commercial Supply Agreement, dated September 5, 2019, by and between the Company and Norbrook (as amended to date, the “Agreement”).”

CADIZ INC entered into Third Amendment to Credit Agreement and First Amendment to Security Agreement with HHC $ Fund 2012 (the "Heerema Lender"), an affiliate of Heerema International Group Services S.A. valued at aggregate principal amount of $20,000,000 (effective 2024-03-06).

“On March 6, 2024, Cadiz Inc. (the “Company,” “we,” “our,” and “us”) and our wholly-owned subsidiaries, Cadiz Real Estate LLC, ATEC Water Systems, LLC, and Octagon Partners LLC (collectively, the “Borrowers”), entered into a Third Amendment to Credit Agreement and First Amendment to Security Agreement (the “Third Amendment”) with HHC $ Fund 2012 (the “Heerema Lender”), an affiliate of Heerema International Group Services S.A. (“Heerema”)”

Perspective Therapeutics, Inc. entered into Placement Agency Agreement with Oppenheimer & Co. Inc. valued at 5.85% of the gross proceeds (effective 2024-03-04).

“The Private Placement was conducted pursuant to a Placement Agency Agreement, dated March 4, 2024 (the “Placement Agency Agreement”), by and between the Company and Oppenheimer & Co. Inc., as representative of the placement agents named therein (the “Placement Agents”).”

Perspective Therapeutics, Inc. entered into Investment Agreement with certain accredited institutional investors valued at approximately $87.4 million (effective 2024-03-04).

“On March 4, 2024, Perspective Therapeutics, Inc. (the “Company”) entered into an investment agreement (the “Investment Agreement”) with certain accredited institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), 92,009,981 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for a purchase price of $0.95 per share, representing the closing price of the Common Stock on March 1, 2024.”

OMNICOM GROUP INC. entered into First Supplemental Indenture with Deutsche Bank Trust Company Americas valued at €600,000,000 aggregate principal amount of 3.700% Senior Notes due 2032 (effective 2024-03-06).

“On March 6, 2024, Omnicom Finance Holdings plc (the “Issuer”), a wholly owned indirect subsidiary of Omnicom Group Inc. (the “Guarantor”), closed its public offering of €600 million aggregate principal amount of 3.700% Senior Notes due 2032 (the “Notes”), which are fully and unconditionally guaranteed by the Guarantor.”

Bunge Global SA amended BFE European Revolving Credit Facility Agreement with Crédit Agricole Corporate and Investment Bank, as agent, and certain lenders valued at $1.75 billion (effective 2024-03-01).

“On March 1, 2024, Bunge Finance Europe B.V. (“ BFE ”), a wholly owned subsidiary of Bunge, exercised the accordion provision set forth in its existing unsecured $1.75 billion 3-year Revolving Credit Agreement (as amended, the “ BFE European Revolving Credit Facility Agreement ”) among BFE, as borrower, Crédit Agricole Corporate and Investment Bank, as agent, and certain lenders party thereto (the “ BFE Lenders ”) pursuant to an accordion increase certificate (the “ BFE Accordion Increase Certificate ”) and an amendment to the BFE European Revolving Credit Facility Agreement (the “ BFE First Amendment ”) in an aggregate amount of $1.75 billion (the “ Additional Commitments ”)”

Bunge Global SA terminated Terminated BLFC-JPM Revolving Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders valued at $1.95 billion (effective 2024-03-01).

“The BLFC-JPM Revolving Credit Agreement replaced an existing U.S. $1.95 billion 5-year First Amended and Restated Revolving Credit Agreement, dated as of June 21, 2023 (the “ Terminated BLFC-JPM Revolving Credit Agreement ”), among BLFC, as borrower, JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders party thereto that was scheduled to mature on July 16, 2026, which was terminated in accordance with its terms on March 1, 2024.”

Bunge Global SA entered into BLFC-JPM Revolving Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders valued at $3.2 billion (effective 2024-03-01).

“On March 1, 2024, Bunge Limited Finance Corp. (“ BLFC ”), a wholly owned subsidiary of Bunge Global SA (“ Bunge ”), entered into an unsecured $3.2 billion 5-year Revolving Credit Agreement (the “ BLFC-JPM Revolving Credit Agreement ”) among BLFC, as borrower, JPMorgan Chase Bank, N.A., as administrative agent, Sumitomo Mitsui Banking Corporation, as syndication agent, Citibank, N.A. and Crédit Agricole Corporate and Investment Bank, as co-documentation agents and certain lenders party thereto”

Kinetic Seas Inc. entered into Connectivity Agreement with Zazo Inc valued at Two year agreement for 10G internet connectivity with 2 fiber optical connections (effective 2023-12-14).

“Effective December 14, 2023, Bellatora Inc (the "Company") and Zazo Inc, ("Zazo") entered into a two year agreement for Zazo to provide 10G internet connectivity with 2 fiber optical connections to the Company's Databank-ORD4 location in Oakbrook Illinois.”

Kinetic Seas Inc. entered into Master Services Agreement and Service Order with Databank Holdings Inc valued at Master Services Agreement and Service Order for server collocation services at Databank-ORD4 (effective 2023-12-14).

“Effective December 14, 2023, Bellatora Inc (the "Company") entered into a Master Services Agreement and Service Order with Databank Holdings Inc, ("Databank") provide the Company with server collocation services at their Databank-ORD4 location in Oakbrook Illinois.”

Kinetic Seas Inc. entered into Letter of Agency with Lightyear AI Inc valued at Letter of Agency for Lightyear to act as agent for communication service purposes (effective 2023-12-14).

“Effective December 14, 2023, Bellatora Inc (the "Company") entered into a Letter of Agency with Lightyear AI Inc ("Lightyear") for Lightyear to act as agent for the Company for the purposes of inspecting, coordinating, discussing, and arranging communication service on behalf of the Company.”

Kinetic Seas Inc. amended Promissory Note Agreement with Coral Investment Partners, LP. valued at Amendment to Promissory Note Agreement, including interest-only payments, conversion rights, and ben (effective 2023-12-14).

“Effective December 14, 2023, Bellatora, Inc., n/k/a Kinetic Seas Incorporated (the “Company”) and Coral Investment Partners, LP. (“Coral”) agreed to amend their Promissory Note Agreement in the following manner:”

SURF AIR MOBILITY INC. entered into Security Purchase Agreement with GEM Global Yield LLC SCS valued at up to $35,200,000 (effective 2024-03-01).

“On March 1, 2024, Surf Air Mobility, Inc. (the “Company”) entered into a security purchase agreement (the “SPA”) with GEM Global Yield LLC SCS (“GEM”).”

Sixth Street Lending Partners entered into Purchase Agreement with BofA Securities, Inc., as representative of the several initial purchasers valued at $600.0 million (effective 2024-03-04).

“On March 4, 2024, Sixth Street Lending Partners (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) by and among the Company, Sixth Street Lending Partners Advisers, LLC (the “Adviser”) and BofA Securities, Inc., as representative of the several initial purchasers named in Schedule 1 thereto (the “Initial Purchasers”), in connection with the issuance and sale of $600.0 million aggregate principal amount of the Company’s 6.500% Notes due 2029 (the “Notes”) in a private offering to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to non-U.S. persons in transactions outside the United States in reliance on Regulation S under the Securities Act.”

ARES STRATEGIC INCOME FUND entered into Contribution Agreement with ASIF Funding II, LLC (effective 2024-03-01).

“on March 1, 2024, the Fund, as transferor, and the Borrower, as transferee, entered into a Contribution Agreement (the “Contribution Agreement,” and together with the Scotiabank Funding Facility, the “Borrower Agreements”), pursuant to which the Fund will transfer to the Borrower certain originated or acquired loans and related assets (collectively, the “Loans”) from time to time.”

ARES STRATEGIC INCOME FUND entered into Scotiabank Funding Facility with The Bank of Nova Scotia valued at $750 million (effective 2024-03-01).

“On March 1, 2024, Ares Strategic Income Fund (the “Fund”) entered into a Credit Agreement (the “Scotiabank Funding Facility”) with ASIF Funding II, LLC, a wholly owned subsidiary of the Fund, as borrower (the “Borrower”), the Fund, as parent and servicer, the lenders from time to time parties thereto, the Bank of Nova Scotia, as administrative agent, U.S. Bank Trust Company, National Association, as collateral agent and collateral administrator, and U.S. Bank National Association, as custodian and document custodian, that (i) provides a facility amount of $750 million”

Xeris Biopharma Holdings, Inc. entered into Amended and Restated Credit Agreement with Hayfin Services LLP, as administrative agent valued at $200.0 million in term loans (effective 2024-03-05).

“On March 5, 2024, Xeris Biopharma Holdings, Inc. (the “Company”), Xeris Pharmaceuticals, Inc. (“Xeris Pharma”) and certain subsidiary guarantors of the Company entered into an Amended and Restated Credit Agreement and Guaranty (the “Amended and Restated Credit Agreement”) with the lenders from time to time parties thereto (the “New Lenders”) and Hayfin Services LLP, as administrative agent for the New Lenders”

Cadre Holdings, Inc. entered into Incremental Facility Amendment to Credit Agreement and Guaranty Joinder with PNC Bank, National Association valued at $80 million (effective 2024-03-01).

“contemporaneous with the closing of the Alpha Acquisition on March 1, 2024 (the “Closing Date”), the Borrower, as borrower, entered into that certain Incremental Facility Amendment to Credit Agreement and Guaranty Joinder (the “Incremental Facility Amendment”), with the Company, as a Guarantor together with the other Guarantors party thereto, the Lenders party thereto, and PNC Bank, National Association, as Administrative Agent and Swingline Loan Lender”

Stronghold Digital Mining, Inc. entered into Electricity Sales and Purchase Agreements with Champion Energy Services, LLC valued at $425,000 deposit per subsidiary; estimated cost of power approximately $10-12/MWh plus wholesale pow (effective 2024-02-29).

“On February 29, 2024, each of Stronghold Digital Mining Inc.’s (the “Company”) wholly owned subsidiaries, Scrubgrass Reclamation Company, L.P. (“Scrubgrass”) and Panther Creek Power Operating, LLC (“Panther Creek”) entered into Electricity Sales and Purchase Agreements (collectively, the “ESPAs”) and Transaction Addendums (collectively, the “Addendums”) with Champion Energy Services, LLC (“Champion”).”

Future Health ESG Corp. entered into Roth Fee Modification Agreement with Roth Capital Partners LLC valued at Underwriters agreed to accept, in lieu of $300,000 cash fee, either shares of New Common Stock (mini (effective 2024-03-05).

“Also on March 5, 2024, the Company and Roth entered into a fee modification agreement (the "Roth Fee Modification Agreement" and, together with the Cantor Fee Modification Agreement, the "Fee Modification Agreements"), pursuant to which, among other things, Roth agreed to accept, in lieu of payment of the Roth Fee in cash at the Closing, either, in the Company’s sole discretion, (1) a certain number of shares of New Common Stock equal to the greater of (a) 10,000 and (b) the quotient obtained by dividing (x) $100,000 by (y) the VWAP (as defined in the Roth Fee Modification Agreement) of the New Common Stock over the three trading days immediately preceding the date of the initial filing of the re-sale registration statement on Form S-1 or F-1 (or any successor form, as applicable) to register the re-sale of such securities (the "Roth Fee Shares"), or (2) a non-refundable cash fee of $100,000.”

Future Health ESG Corp. entered into Cantor Fee Modification Agreement with Cantor Fitzgerald & Co. valued at Underwriters agreed to accept, in lieu of $8,700,000 deferred fee, either shares of New Common Stock (effective 2024-03-05).

“On March 5, 2024, the Company and Cantor entered into a fee modification agreement (the "Cantor Fee Modification Agreement"), pursuant to which, among other things, Cantor agreed to accept, in lieu of payment of the Cantor Deferred Fee in cash at the Closing, either, in the Company’s sole discretion, (1) a certain number of shares of the publicly traded common equity securities of the resulting public entity following the Company’s initial business combination (the "New Common Stock") equal to the greater of (a) 290,000 and (b) the quotient obtained by dividing (x) $2,900,000 by (y) the VWAP (as defined in the Cantor Fee Modification Agreement) of the New Common Stock over the three trading days immediately preceding the date of the initial filing of the re-sale registration statement on Form S-1 or F-1 (or any successor form, as applicable) to register the re-sale of such securities (the "Cantor Fee Shares"), or (2) a non-refundable cash fee of $2,900,000.”

Future Health ESG Corp. amended Amendment to Purchase and Sponsor Handover Agreement with Blufire Capital Limited valued at Amendment conditions Sponsor Handover on underwriters having $3,000,000 in cash or shares of Common (effective 2024-03-05).

“On March 5, 2024, Future Health, the New Sponsor and the Sponsor entered into an amendment to the Purchase and Sponsor Handover Agreement (the "First Amendment"), pursuant to which the Sponsor Handover is conditioned on, among other things, (i) the underwriters of Future Health’s initial public offering having in the aggregate either, at Future Health’s option, (a) $3,000,000 in cash or (b) a number of shares of Common Stock equal to the greater of (1) 300,000 and (2) the quotient obtained by dividing (x) $3,000,000 by (y) the three-day VWAP (as defined in the First Amendment) of the Common Stock over the three trading days immediately preceding the date of the initial filing of the re-sale registration statement on Form S-1 or F-1 (or any successor form, as applicable) to register the re-sale of such securities.”

Context Therapeutics Inc. amended Integral License Agreement with Integral Molecular, Inc. (effective 2024-02-29).

“Context Therapeutics Inc. (the “Company”) amended its collaboration and licensing agreement with Integral Molecular, Inc. (“Integral”) (the “Integral License Agreement”)”

GPGI, Inc. amended Amendment No. 2 to Third Amended and Restated Credit Agreement with JPMorgan Chase Bank, National Association, as administrative agent, and the lenders party thereto valued at not to exceed $40,000,000 (effective 2024-03-01).

“On March 1, 2024, CompoSecure Holdings, L.L.C. (“Holdings”), CompoSecure, L.L.C. (“CompoSecure”), Arculus Holdings, L.L.C. (“Arculus” and collectively with Holdings and CompoSecure, the “Companies”), JPMorgan Chase Bank, National Association, as administrative agent (“JPMC”), and the lenders party thereto, entered into Amendment No. 2 to Third Amended and Restated Credit Agreement (the “Second Amendment”).”

Cipher Digital Inc. amended Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., Canaccord Genuity LLC, Compass Point Research & Trading, LLC, Needham & Company, LLC, Stifel, Nicolaus & Company, Incorporated and Virtu Americas LLC valued at Amendment adds Stifel, Nicolaus & Company, Incorporated and Virtu Americas LLC as additional agents (effective 2024-03-06).

“On March 6, 2024, Cipher Mining Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) by and among Cantor Fitzgerald & Co., Canaccord Genuity LLC, Compass Point Research & Trading, LLC, Needham & Company, LLC, Stifel, Nicolaus & Company, Incorporated and Virtu Americas LLC.”

NEXTNRG, INC. entered into the "Note" with Next Charging, LLC valued at $165,000 (effective 2024-02-29).

“On February 29, 2024, EzFill Holdings, Inc. (the “Company”) and Next Charging, LLC (“Next”) entered into a promissory note (the “Note”) for the sum of $165,000 (the “Loan”) to be used for the Company’s working capital needs, which Note has an effective date of February 28, 2024.”

Blue Owl Credit Income Corp. amended Amendment No. 1 with The Bank of Nova Scotia, as Administrative Agent, State Street Bank and Trust Company, as Collateral Agent, Collateral Administrator and Document Custodian, and Hamburg Commercial Bank AG, Luxembourg Branch valued at converted $140,000,000 of revolving commitments to term commitments (effective 2024-03-01).

“On March 1, 2024 (the “Amendment Date”), Core Income Funding VI LLC (“Core Income Funding VI”), a subsidiary of Blue Owl Credit Income Corp. (the “Company”), (i) entered into Amendment No. 1 (the “Amendment No. 1” and the facility as amended, the “Credit Facility”), which amended that certain Credit Agreement, dated as of August 29, 2023”

Akero Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C. valued at approximately $299.4 million (effective 2024-03-05).

“On March 5, 2024, Akero Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C. as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell 11,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), to the Underwriters at a public offering price of $29.00 per share (the “ Offering ”).”

BridgeBio Pharma, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters valued at approximately $250.0 million (effective 2024-03-05).

“On March 5, 2024, BridgeBio Pharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 8,620,690 shares of the Company's common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $29.00 per share.”

BiomX Inc. entered into Agreement and Plan of Merger with Adaptive Phage Therapeutics, Inc. (effective 2024-03-06).

“On March 6, 2024, BiomX Inc., Inc., a Delaware corporation (the “Company” or “BiomX”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, BTX Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“First Merger Sub”), BTX Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Second Merger Sub”), and Adaptive Phage Therapeutics, Inc., a Delaware corporation (“APT”).”

Crypto Co entered into Securities Purchase Agreement with AJB Capital Investments, LLC valued at $159,000 (effective 2024-02-29).

“The Crypto Company (the “Company”) borrowed funds pursuant to the terms of a Securities Purchase Agreement (the “AJB SPA”) entered into with AJB Capital Investments, LLC (“AJB”), and issued a Promissory Note in the principal amount of $159,000 (the “AJB Note”) to AJB in a private transaction for a purchase price of $135,000, each dated as of February 29, 2024.”

Merus N.V. entered into Share Subscription Agreement with Gilead Sciences, Inc. (effective 2024-03-05).

“On March 5, 2024, we entered into a collaboration, option and license agreement (“Collaboration Agreement”) and Share Subscription Agreement (the “Subscription Agreement”) with Gilead Sciences, Inc. (“Gilead”).”

Merus N.V. entered into Collaboration Agreement with Gilead Sciences, Inc. valued at $56 million (effective 2024-03-05).

“On March 5, 2024, we entered into a collaboration, option and license agreement (“Collaboration Agreement”) and Share Subscription Agreement (the “Subscription Agreement”) with Gilead Sciences, Inc.”

Evofem Biosciences, Inc. entered into December Assignment Agreement with Aditxt, Inc. and certain holders of Company senior indebtedness notes (effective 2023-12-11).

“Aditxt entered into an assignment agreement, dated December 11, 2023 (the “December Assignment Agreement”) pursuant to which Aditxt and certain holders of Company senior indebtedness notes (the “Holders”) assigned their respective notes to Aditxt in consideration for the issuance, by Aditxt, of (i) an aggregate principal amount of $5.0 million in secured notes of the Company due on January 2, 2024 (the “January 2024 Secured Notes”), (ii) an aggregate principal amount of $8.0 million in secured notes of the Company due on September 30, 2024 (the “September 2024 Secured Notes”), (iii) an aggregate principal amount of $5.0 million in ten-year unsecured notes (the “Unsecured Notes”), and (iv) payment of $154,480 in respect of net sales of Phexxi in respect of the calendar quarter ended September 30, 2023 (the payment, together with the September 2024 Notes, the December 2023 Notes and the Unsecured Notes, as may have been amended from time to time, the “Notes”).”

Evofem Biosciences, Inc. entered into Agreement and Plan of Merger with Aditxt, Inc. and Adicure, Inc. (effective 2023-12-11).

“on December 11, 2023 the Company, Aditxt, Inc., a Delaware Corporation (“Aditxt”) and Adicure, Inc., a Delaware corporation and wholly-owned subsidiary of the Parent (the “Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), whereby the Merger Sub will merge with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the “Merger”).”

Duolingo, Inc. amended First Amendment to the Lease with 5704 Penn Office, LLC valued at approximately $188,000 per month; approximately $394,000 per month; improvement allowance of up to a (effective 2024-03-04).

“On March 4, 2024, the Company entered into the First Amendment to the Lease (the “First Amendment”), which, among other things, increases the leased square footage by 110,008 square feet to a total of 148,266 square feet beginning on August 1, 2025, with an expiration date of April 30, 2036.”

Diamondback Energy, Inc. amended Fourteenth Amendment with Wells Fargo Bank, National Association, as administrative agent (effective 2024-03-06).

“On March 6, 2024, the Company and the Borrower entered into a fourteenth amendment (the “Revolving Amendment”) to the Second Amended and Restated Credit Agreement, dated as of November 1, 2013, with Wells Fargo Bank, National Association, as administrative agent (the “Administrative Agent”), and the lenders party thereto (as amended, supplemented or otherwise modified prior to the date of the Revolving Amendment and as further amended by the Revolving Amendment, the “Revolving Credit Agreement”).”